

Chris J Packard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3538294/publications.pdf>

Version: 2024-02-01

59
papers

10,559
citations

117625
34
h-index

138484
58
g-index

60
all docs

60
docs citations

60
times ranked

12414
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
2	Major Lipids, Apolipoproteins, and Risk of Vascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1993.	7.4	2,205
3	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
4	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	13.7	512
5	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. <i>European Heart Journal</i> , 2021, 42, 2439-2454.	2.2	491
6	Association of Triglyceride-Lowering <i>LPL</i> Variants and LDL-Câ€“Lowering <i>LDLR</i> Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 364.	7.4	460
7	Association of <i>LPA</i> Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. <i>JAMA Cardiology</i> , 2018, 3, 619.	6.1	428
8	Lipoprotein Heterogeneity and Apolipoprotein B Metabolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3542-3556.	2.4	352
9	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	2.2	303
10	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	7.4	247
11	High-Sensitivity Cardiac Troponin, StatinÂTherapy, and Risk of CoronaryÂHeartÂDisease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2719-2728.	2.8	199
12	Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy. <i>Circulation</i> , 2016, 133, 1073-1080.	1.6	190
13	Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. <i>Lancet, The</i> , 2012, 379, 915-922.	13.7	179
14	Dietary Fructose and the Metabolic Syndrome. <i>Nutrients</i> , 2019, 11, 1987.	4.1	152
15	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. <i>Circulation</i> , 2017, 136, 1878-1891.	1.6	144
16	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1381.	7.4	144
17	Causes and Consequences of Hypertriglyceridemia. <i>Frontiers in Endocrinology</i> , 2020, 11, 252.	3.5	122
18	A new combined multicompartamental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. <i>Journal of Lipid Research</i> , 2005, 46, 58-67.	4.2	108

#	ARTICLE	IF	CITATIONS
19	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
20	Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis, 2002, 164, 129-145.	0.8	81
21	The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. Frontiers in Endocrinology, 2020, 11, 474.	3.5	81
22	Non-HDL Cholesterol as a Measure of Atherosclerotic Risk. Journal of Atherosclerosis and Thrombosis, 2004, 11, 6-14.	2.0	77
23	Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD. Current Atherosclerosis Reports, 2019, 21, 27.	4.8	72
24	“Highest risk”-“highest benefit” strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal, 2018, 39, 2546-2550.	2.2	69
25	Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1949-1952.	0.9	63
26	Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nature Reviews Cardiology, 2022, 19, 577-592.	13.7	59
27	Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis. Journal of Nutrition, 2016, 146, 516-523.	2.9	56
28	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. Current Atherosclerosis Reports, 2019, 21, 41.	4.8	53
29	Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart, 2021, 107, 1369-1375.	2.9	53
30	Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias. Journal of the American College of Cardiology, 2020, 76, 563-579.	2.8	52
31	Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels. Nature Communications, 2015, 6, 6065.	12.8	45
32	Role of apolipoprotein C overproduction in diabetic dyslipidaemia. Diabetes, Obesity and Metabolism, 2019, 21, 1861-1870.	4.4	39
33	Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight, 2020, 5, .	5.0	38
34	Smoking and Plasma Lipoprotein Metabolism. Clinical Science, 1995, 89, 333-342.	4.3	35
35	Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Current Opinion in Cardiology, 2009, 24, 358-363.	1.8	35
36	Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. Journal of Clinical Lipidology, 2020, 14, 77-87.	1.5	26

#	ARTICLE	IF	CITATIONS
37	Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1191-1201.	4.4	20
38	Long-term follow-up of lipid-lowering trials. <i>Current Opinion in Lipidology</i> , 2015, 26, 572-579.	2.7	18
39	Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 962-975.	2.4	18
40	Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2022, 24, 133-142.	4.8	17
41	Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. <i>Clinica Chimica Acta</i> , 2017, 466, 13-19.	1.1	16
42	Association of oily fish intake, sex, age, BMI and APOE genotype with plasma long-chain n-3 fatty acid composition. <i>British Journal of Nutrition</i> , 2018, 120, 23-32.	2.3	15
43	UK Food Standards Agency cis-monounsaturated fatty acid workshop report. <i>British Journal of Nutrition</i> , 2002, 88, 99-104.	2.3	14
44	Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice. <i>Current Opinion in Lipidology</i> , 2018, 29, 51-52.	2.7	14
45	Keeping remnants in perspective. <i>European Heart Journal</i> , 2021, 42, 4333-4335.	2.2	13
46	LDL cholesterol: How low to go?. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 348-354.	4.9	12
47	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021, 320, 1-9.	0.8	11
48	Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism. <i>Circulation</i> , 2017, 135, 363-365.	1.6	8
49	Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias. <i>Current Cardiology Reports</i> , 2018, 20, 60.	2.9	8
50	Triglyceride lowering 2.0: back to the future?. <i>European Heart Journal</i> , 2020, 41, 95-98.	2.2	7
51	A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. <i>Atherosclerosis Supplements</i> , 2006, 7, 21-29.	1.2	6
52	Effects of PNPLA3 I148M on hepatic lipid and very-low-density lipoprotein metabolism in humans. <i>Journal of Internal Medicine</i> , 2022, 291, 218-223.	6.0	5
53	Strategies to alter the trajectory of atherosclerotic cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2019, 30, 438-445.	2.7	4
54	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003219.	3.6	4

#	ARTICLE	IF	CITATIONS
55	Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. European Heart Journal Quality of Care & Clinical Outcomes, 2017, 3, 281-288.	4.0	2
56	Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism. European Journal of Endocrinology, 2022, 187, 75-84.	3.7	2
57	Response by Vallejo-Vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up". Circulation, 2018, 137, 2419-2420.	1.6	1
58	Lipid-lowering drug therapies: the evidence. Proceedings of the Nutrition Society, 2000, 59, 423-424.	1.0	0
59	Letter by Packard Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial". Circulation, 2020, 142, e333-e334.	1.6	0